Seniors’ Access to Critical Medications Act of 2023

H.R. 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; Access and reimbursement of Part B Drugs in Medicare; Continued expansion of Telehealth services including in H.R. 3875/S. 3967, Expanded Telehealth Access Act and Telehealth Modernization Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (PATIENT Act) of 2023; H.R. 4822, Health Care Price Transparency Act of 2023; Support for site neutrality policies in H.R. 5378, Lower Costs, More Transparency Act; Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022; Issues related to MACRA Reform including H.R. 2474, Strengthening Medicare for Patients and Providers Act; Support the passage of H.R. 5526/S. 3458, the Seniors' Access to Critical Medications Act; H.R. 6683, Preserving Seniors Access to Physicians Act of 2023; Issues related to prior authorization in H.R. 8702/S. 4518, Improving Seniors Timely Access to Care Act of 2024; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Telehealth extension; Issues related to site neutral payments; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764/H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Telehealth extension; Issues related to site neutral payments; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764/H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposed modifications to the existing definition of distributor bona fide service fees The Equitable Community Access to Pharmacist Services Act (H.R. 1770/ S.2477) Inflation Reduction Act Extend payment increase under Medicare's physician fee schedule. Medicare Access & CHIP Reauthorization Act (MACRA). Physician Medicare reimbursement annual fee update. Pharmacy and Medically Underserved Areas Enhancement Act (S.1491). Seniors Access to Critical Medicines Act (H.R. 5526/S.3458). Protecting Patient Access to Cancer and Complex Therapies Act (S. 2764). Reimbursement policies impacting drug shortages Part B drug pricing changes Enhanced Oncology Model (EOM) Preventing and Mitigating Generic Drug Shortages Senate Finance Draft Medicare Drug Shortage Prevention Policies

Client expense: $1,100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Strategic National Stockpile. Essential Medicines Strategic Stockpile Act (H.R.405). Prescription Information Modernization Act (H.R.1503/S.2916). Drug Shortages Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S.2510/H.R.6802). SUPPORT Act Reauthorization (S.2433/H.R.4531). FY2025 National Defense Authorization Act. House E&C Drug Shortages Discussion Draft. FY 2024 Continuing Resolution. Seniors Access to Critical Medications Act of 2023 (H.R. 5526/S.3458) Department of Defense Essential Medicines Strategic Stockpile Amendment to NDAA Health Care Cybersecurity Improvement Act of 2024 (S.4054) Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act (H.R.9886/S.5271)

Client expense: $1,100,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, White House Office

Pharmacy and Medically Underserved Area Enhancement Act (S.1491). Preventing and Mitigating Generic Drug Shortages The Equitable Community Access to Pharmacist Services Act (H.R. 1770/S.2477). Seniors Access to Critical Medications Act of 2023 (H.R. 5526/S.3458) House and Senate Agriculture, FDA and related agency Appropriation bills House and Senate Labor/HHS Appropriations bills

Client expense: $1,100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

Access and reimbursement of Part B Drugs in Medicare. Extension of certain telehealth flexibilities included in H.R. 10545 the American Relief Act, 2025 Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Issues related to physician payment included in H.R.10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R.5526/S.3458 - Seniors Access to Critical Medications Act of 2023. H.R.10545, FY25 Continuing Appropriations.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R.5526/S.3458 - Seniors Access to Critical Medications Act of 2023. H.R.10545, FY25 Continuing Appropriations.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 5526/S. 3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 5526/S. 3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526 / S. 3458, 118th Congress).

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes. HR 6992: Mapping America's Pharmaceutical Supply Act- require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain. S 3458: Seniors' Access to Critical Medications Act of 2023 - clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program. HR 8404/S 4330: ROCR Value Based Program Act of 2024 - To amend title XVIII of the Social Security Act to create a Radiation Oncology Case Rate Value Based Payment Program exempt from budget neutrality adjustment requirements, and to amend section 1128A of title XI of the Social Security Act to create a new statutory exception for the provision of free or discounted transportation for radiation oncology patients to receive radiation therapy services. HR 3633: Prevent HPV Cancers ACt of 2023 - To amend the Public Health Service Act to provide for a public awareness campaign with respect to human papillomavirus, and for other purposes. HR 3008: Drug Shortage Prevention Act of 2023 - To amend the Federal Food, Drug, and Cosmetic Act to provide for notification by manufacturers of critical essential medicines of increased demand of such drugs, and for other purposes. S 5368/HR 10239: End Drug Shortages Act - To amend the Federal Food, Drug, and Cosmetic Act to expand drug shortage notification practices to include surges in demand for a drug, and for other purposes.

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CMS FAQ on Stark mailing drugs violation (H.R. 5526) (S. 3458) Continuing Resolution Multiple pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting) Pharmacy Benefit Manager Transparency Act (S. 127) Misc. 340B Drug Discount Program issues (no specific bill number) Hospital site-neutral payments (no specific bill number) Medicare physician payment issues (no specific bill number) Inflation Reduction Act (H.R. 5376) Enhancing Oncology Model (CMMI)

Client expense: $285,800 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cybersecurity concerns and pharmacy access and payment; IRA implementation; S.3458/H.R.5526 Seniors Access to Critical Medications Act.

Client expense: Not reported · Firm income: $120,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 8702 / S 4532, Improving Seniors Timely Access to Care Act; HR 1613, the Drug Price Transparency in Medicaid Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act; S 4349, the Electronic Prior Authorization for Prescription Drugs Act Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $160,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Proposed modifications to the existing definition of distributor bona fide service fees The Equitable Community Access to Pharmacist Services Act (H.R. 1770/ S.2477). Extend payment increase under Medicare's physician fee schedule. Medicare Access & CHIP Reauthorization Act (MACRA). Physician Medicare reimbursement annual fee update. Pharmacy and Medically Underserved Areas Enhancement Act (S.1491). Seniors Access to Critical Medicines Act (H.R. 5526/S.3458). Protecting Patient Access to Cancer and Complex Therapies Act (S. 2764). Reimbursement policies impacting drug shortages Part B drug pricing changes Enhanced Oncology Model (EOM) Preventing and Mitigating Generic Drug Shortages Senate Finance Draft Medicare Drug Shortage Prevention Policies

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Strategic National Stockpile. Essential Medicines Strategic Stockpile Act (H.R.405). Ensuring essential medication supply for military and Department of Defense. Prescription Information Modernization Act (H.R.1503/S.2916). Drug Shortages Pandemic and All Hazards Preparedness Reauthorization and Response Act (legislation). Drug Supply Chain Security Act Implementation (DSCSA). Rolling Active Pharmaceutical Ingredient and Drug (RAPID) Reserve Act (S.2510/H.R.6802). SUPPORT Act Reauthorization (S.2433/H.R.4531). FY2025 National Defense Authorization Act. House E&C Drug Shortages Discussion Draft. FY 2024 Continuing Resolution. Seniors Access to Critical Medications Act of 2023 (H.R. 5526/S.3458) Department of Defense Essential Medicines Strategic Stockpile Amendment to NDAA Health Care Cybersecurity Improvement Act of 2024 (S.4054) Drug Supply Chain Security Act (DSCSA)

Client expense: $570,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE

Pharmacy and Medically Underserved Area Enhancement Act (S.1491). House and Senate Agriculture, FDA, and related agency Appropriations bills. House and Senate Labor/HHS appropriations bills. Preventing and Mitigating Generic Drug Shortages The Equitable Community Access to Pharmacist Services Act (H.R. 1770/S.2477). Seniors Access to Critical Medications Act of 2023 (H.R. 5526/S.3458)

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; Access and reimbursement of Part B Drugs in Medicare; Continued expansion of Telehealth services including in H.R. 3875/S. 3967, Expanded Telehealth Access Act and Telehealth Modernization Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (PATIENT Act) of 2023; H.R. 4822, Health Care Price Transparency Act of 2023; Support for site neutrality policies in H.R. 5378, Lower Costs, More Transparency Act; Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022; Issues related to MACRA Reform including H.R. 2474, Strengthening Medicare for Patients and Providers Act; Support the passage of H.R. 5526/S. 3458, the Seniors' Access to Critical Medications Act; H.R. 6683, Preserving Seniors Access to Physicians Act of 2023; Issues related to prior authorization in H.R. 8702/S. 4518, Improving Seniors Timely Access to Care Act of 2024

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Telehealth extension; Issues related to site neutral payments; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764/H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in H.R. 3875/S.3967 - Expanded Telehealth Access Act and H.R. 7623 - Telehealth Modernization Act of 2024. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3875 - Expanded Telehealth Access Act and H.R. 7623 - Telehealth Modernization Act of 2024. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R.5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R.5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CMS FAQ on Stark mailing drugs violation (H.R. 5526) (S. 3458) Multiple pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting) Pharmacy Benefit Manager Transparency Act (S. 127) Misc. 340B Drug Discount Program issues (no specific bill number) Hospital site-neutral payments (no specific bill number) Medicare physician payment issues (no specific bill number) Inflation Reduction Act (H.R. 5376) Enhancing Oncology Model (CMMI)

Client expense: $246,500 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes. HR 6992: Mapping America's Pharmaceutical Supply Act- require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain. S 3458: Seniors' Access to Critical Medications Act of 2023 - clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program. HR 8404/S 4330: ROCR Value Based Program Act of 2024 - To amend title XVIII of the Social Security Act to create a Radiation Oncology Case Rate Value Based Payment Program exempt from budget neutrality adjustment requirements, and to amend section 1128A of title XI of the Social Security Act to create a new statutory exception for the provision of free or discounted transportation for radiation oncology patients to receive radiation therapy services.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R.5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: Not reported

Issues related to H.R.5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: Not reported

Telehealth extension; Issues related to site neutral payments; Issues related to healthcare transparency and consolidation; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764 / H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Telehealth extension; Issues related to site neutral payments; Issues related to healthcare transparency and consolidation; Issues related to prior authorization in Medicare Advantage; Issues related to physician payment reform; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 5526/S.3458, Seniors Access to Critical Medications Act of 2023; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3284, Providers and Payers COMPETE Act; S. 2764/H.R. 5391, Protecting Patient Access to Cancer and Complex Therapies Act of 2023; H.R. 5378, The Lower Costs, More Transparency Act

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 652/HR 2630: Safe Step Act- implementing safe guards around step therapy (fail first) programs in ERISA regulated plan S 1375/HR 830: HELP Copays Act- copay accumulator programs Addressing Pharmacy Benefit Managers S 127: Pharmacy Benefit Manager Transparency Act of 2023- prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs S 79: Interagency Patent Coordination and Improvement Act of 2023- establishes an interagency taskforce between the United States Patent and Trademark Office and the FDA S 2243: Palliative Care and Hospice Education and Training Act (PCHETA)- promote education and research in palliative care and hospice Palliative care S 2213: Comprehensive Cancer Survivorship Act- cancer survivorship S 2039: Cancer Drug Parity Act of 2023- oral parity for cancer drugs HR 3633: PREVENT HPV Cancers Act of 2023 S 1624/HR 3391: Gabriella Miller Kids First Research Act 2.0- pediatric cancer research Addressing healthcare workforce shortages Increasing diversity in clinical trials Mitigating drug shortages and increasing supply chain resiliency and future pandemic preparedness, including bolstering the strategic national stockpile S 1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023- require an interagency risk assessment of the pharmaceutical supply chain to identify and mitigate health and national security risks HR 3810: Drug Origin Transparency Act of 2023 - Require drug manufacturers to report to the Food and Drug Administration (FDA) quarterly the supplier's location and drug ingredients HR 3793: Ensuring Access to Lifesaving Drugs Act of 2023 - require manufacturers of life-saving drugs to submit data and information to assess the stability of the drugs and determine their longest supported expiration date, and for other purposes. S 2364: MAPS ACT - A bill to map the United States pharmaceutical supply chain S 2510: RAPID Reserve Act - establish reserves of both Active Pharmaceutical Ingredients (APIs) and finished drug products to be held as vendor-managed inventory and used when needed to prevent supply disruptions HR 5526: Seniors' Access to Critical Medications Act of 2023 - make permanent a waiver issued by the Centers for Medicare and Medicaid Services (CMS) that allowed for Medicare patients to receive critical medications by mail or allow for caregivers and family members to obtain medications for them. HR 6301: Cancer Drug Parity Act of 2023 - To amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider. HR 6963: To direct the Secretary of Health and Human Services to enter into agreements with drug manufacturers to establish reserve supplies of covered pediatric cancer drugs, and for other purposes - establish reserve supplies of covered pediatric cancer drugs, and for other purposes. HR 6992: Mapping America's Pharmaceutical Supply Act- require the Department of Health and Human Services to update its essential medicines list and create a database to help predict vulnerabilities in the U.S. pharmaceutical supply chain. S 3458 Seniors' Access to Critical Medications Act of 2023 - clarify the application of the in-office ancillary services exception to the physician self-referral prohibition for drugs furnished under the Medicare program.

Client expense: $540,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 1613, the Drug Price Transparency in Medicaid Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S. 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Proposed modifications to the existing definition of distributor bona fide service fees The Equitable Community Access to Pharmacist Services Act (H.R. 1770/ S.2477). Inflation Reduction Act. Extend payment increase under Medicare's physician fee schedule. Medicare Access & CHIP Reauthorization Act (MACRA). Physician Medicare reimbursement annual fee update. Pharmacy and Medically Underserved Areas Enhancement Act (S.1491). Seniors Access to Critical Medicines Act (H.R. 5526/S.3458). Protecting Patient Access to Cancer and Complex Therapies Act (S. 2764). Reimbursement policies impacting drug shortages. Part B drug pricing changes. Enhanced Oncology Model (EOM). Preventing and Mitigating Generic Drug Shortages: Policy Options Senate Finance Draft Medicare Drug Shortage Prevention Policies Medicaid Stacking Issues

Client expense: $440,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare reimbursement of certain oncology drugs. Issues related to the Seniors Access to Critical Medications Act of 2023 (H.R. 5526 / S. 3458).

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in the H.R. 3857 - Expanded Telehealth Access Act and Telehealth Modernization Act. Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.5391, S. 2764 - Protecting Patient Access to Cancer and Complex Therapies Act Access and reimbursement of Part B Drugs in Medicare. Continued expansion of Telehealth services including in H.R. 3857/S.3967 - Expanded Telehealth Access Act and Telehealth Modernization Act. H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. H.R.4822 - Health Care Price Transparency Act of 2023 Support for site neutrality policies in H.R.5378 - Lower Costs, More Transparency Act Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to MACRA Reform including HR 2474 - Strengthening Medicare for Patients and Providers Act. Support the passage of the Seniors' Access to Critical Medications Act (H.R. 5526, S. 3458) H.R.6683 - Preserving Seniors Access to Physicians Act of 2023 Issues related to prior authorization in H.R. 8702/S. 4518 - Improving Seniors' Timely Access to Care Act

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

CMS FAQ on Stark mailing drugs violation (H.R. 5526) (S. 3458) Multiple pharmacy benefit managers (PBMs) issues relating to cancer care (general issues and multiple bills supporting) Change Healthcare cyber attack Pharmacy Benefit Manager Transparency Act (S. 127) Misc. 340B Drug Discount Program issues (no specific bill number) Hospital site-neutral payments Medicare physician payment issues (no specific bill number) Inflation Reduction Act (H.R. 5376) Cancer drug shortages (no specific bill number) Enhancing Oncology Model (CMMI)

Client expense: $288,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 5526/S.3458 - SeniorsAccess to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to H.R. 5526/S.3458 - Seniors Access to Critical Medications Act of 2023.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to HR 5526, S3458 - Seniors Access to Critical Medications Act of 2023

Client expense: Not reported · Firm income: Not reported

Issues related to HR 5526, S3458 - Seniors Access to Critical Medications Act of 2023

Client expense: Not reported · Firm income: Not reported

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S. 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act HR 1613, the Drug Price Transparency in Medicaid Act; Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office